Cargando…
The journey of antimalarial drugs against SARS-CoV-2: Review article
The recent outbreak of coronavirus pandemic (COVID-19) introduced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has greatly affected the global public health. This pandemic disease became particularly threatening after the start of a new wave. Vaccines of tested efficacy to stop CO...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132553/ https://www.ncbi.nlm.nih.gov/pubmed/34028468 http://dx.doi.org/10.1016/j.imu.2021.100604 |
_version_ | 1783694935687430144 |
---|---|
author | Sarhan, Amany A. Ashour, Nada A. Al‐Karmalawy, Ahmed A. |
author_facet | Sarhan, Amany A. Ashour, Nada A. Al‐Karmalawy, Ahmed A. |
author_sort | Sarhan, Amany A. |
collection | PubMed |
description | The recent outbreak of coronavirus pandemic (COVID-19) introduced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has greatly affected the global public health. This pandemic disease became particularly threatening after the start of a new wave. Vaccines of tested efficacy to stop COVID-19 infection are being investigated vigorously worldwide. Currently, some specific drugs have been authorized for COVID-19, but the improvement of antivirals requires time. Hence, a faster way of treatment is done by drug repurposing. Repurposing of drugs is promising for treating and reducing the symptoms of the disease, and it a fast, easy, and safe method to address the crisis, because of their previously known applications. Some antimalarial drugs, especially chloroquine and hydroxychloroquine, have been repurposed, as they exhibited promising results in vitro and in vivo. This article investigates repurposed antimalarial drugs, focusing on their antiviral mechanisms of action, effects in combinations, trial results, and their side effects. |
format | Online Article Text |
id | pubmed-8132553 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Authors. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81325532021-05-19 The journey of antimalarial drugs against SARS-CoV-2: Review article Sarhan, Amany A. Ashour, Nada A. Al‐Karmalawy, Ahmed A. Inform Med Unlocked Article The recent outbreak of coronavirus pandemic (COVID-19) introduced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has greatly affected the global public health. This pandemic disease became particularly threatening after the start of a new wave. Vaccines of tested efficacy to stop COVID-19 infection are being investigated vigorously worldwide. Currently, some specific drugs have been authorized for COVID-19, but the improvement of antivirals requires time. Hence, a faster way of treatment is done by drug repurposing. Repurposing of drugs is promising for treating and reducing the symptoms of the disease, and it a fast, easy, and safe method to address the crisis, because of their previously known applications. Some antimalarial drugs, especially chloroquine and hydroxychloroquine, have been repurposed, as they exhibited promising results in vitro and in vivo. This article investigates repurposed antimalarial drugs, focusing on their antiviral mechanisms of action, effects in combinations, trial results, and their side effects. The Authors. Published by Elsevier Ltd. 2021 2021-05-19 /pmc/articles/PMC8132553/ /pubmed/34028468 http://dx.doi.org/10.1016/j.imu.2021.100604 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Sarhan, Amany A. Ashour, Nada A. Al‐Karmalawy, Ahmed A. The journey of antimalarial drugs against SARS-CoV-2: Review article |
title | The journey of antimalarial drugs against SARS-CoV-2: Review article |
title_full | The journey of antimalarial drugs against SARS-CoV-2: Review article |
title_fullStr | The journey of antimalarial drugs against SARS-CoV-2: Review article |
title_full_unstemmed | The journey of antimalarial drugs against SARS-CoV-2: Review article |
title_short | The journey of antimalarial drugs against SARS-CoV-2: Review article |
title_sort | journey of antimalarial drugs against sars-cov-2: review article |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132553/ https://www.ncbi.nlm.nih.gov/pubmed/34028468 http://dx.doi.org/10.1016/j.imu.2021.100604 |
work_keys_str_mv | AT sarhanamanya thejourneyofantimalarialdrugsagainstsarscov2reviewarticle AT ashournadaa thejourneyofantimalarialdrugsagainstsarscov2reviewarticle AT alkarmalawyahmeda thejourneyofantimalarialdrugsagainstsarscov2reviewarticle AT sarhanamanya journeyofantimalarialdrugsagainstsarscov2reviewarticle AT ashournadaa journeyofantimalarialdrugsagainstsarscov2reviewarticle AT alkarmalawyahmeda journeyofantimalarialdrugsagainstsarscov2reviewarticle |